Adverse events associated with ulocuplumab and ibrutinib therapy in 13 patients with WM
| Adverse event . | Grade 2 . | Grade 3 . | Grade 4 . | Total grades 2 to 4 . |
|---|---|---|---|---|
| Blood and lymphatic system disorders | ||||
| Anemia | 1 | 0 | 0 | 1 |
| Thrombocytopenia | 4 | 3 | 1 | 8 |
| Neutropenia | 0 | 0 | 1 | 1 |
| Cardiac disorders | ||||
| Atrial fibrillation | 1 | 0 | 0 | 1 |
| Supraventricular tachycardia | 0 | 1 | 0 | 1 |
| Palpitations | 1 | 0 | 0 | 1 |
| Constitutional | ||||
| Chills | 1 | 0 | 0 | 1 |
| Fatigue | 4 | 0 | 0 | 4 |
| Gastrointestinal disorders | ||||
| Diarrhea | 3 | 0 | 0 | 3 |
| Gastric ulcer/gastritis | 1 | 0 | 0 | 1 |
| Gastroesophageal reflux disease | 1 | 0 | 0 | 1 |
| Mucositis oral | 1 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 1 |
| General disorders | ||||
| Edema limbs | 1 | 0 | 0 | 1 |
| Infections and infestations | ||||
| Ear infection/otitis media | 2 | 0 | 0 | 2 |
| Eye infection | 1 | 0 | 0 | 1 |
| Lung infection | 2 | 0 | 0 | 2 |
| Dental infection | 1 | 0 | 0 | 1 |
| Sinusitis | 2 | 0 | 0 | 2 |
| Skin infection | 4 | 0 | 0 | 4 |
| Upper respiratory infection | 2 | 0 | 0 | 2 |
| Urinary tract infection | 1 | 0 | 0 | 1 |
| Oral candidiasis | 1 | 0 | 0 | 1 |
| Metabolism and nutrition disorders | ||||
| Hyperglycemia | 1 | 2 | 0 | 3 |
| Hypokalemia | 0 | 1 | 0 | 1 |
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 3 | 0 | 0 | 3 |
| Myalgia | 2 | 0 | 0 | 2 |
| Lightheadedness | 1 | 0 | 0 | 1 |
| Headache | 0 | 1 | 0 | 1 |
| Presyncope | 1 | 0 | 0 | 1 |
| Respiratory, thoracic, and mediastinal disorders | ||||
| Cough | 3 | 0 | 0 | 3 |
| Dyspnea | 2 | 1 | 0 | 3 |
| Hypoxia | 1 | 0 | 0 | 1 |
| Epistaxis | 1 | 0 | 0 | 1 |
| Other | 2 | 0 | 0 | 2 |
| Skin and subcutaneous tissue disorders | ||||
| Skin and subcutaneous tissue disorders, rash | 5 | 1 | 0 | 6 |
| Skin and subcutaneous tissue disorders, other | 1 | 0 | 0 | 1 |
| Adverse event . | Grade 2 . | Grade 3 . | Grade 4 . | Total grades 2 to 4 . |
|---|---|---|---|---|
| Blood and lymphatic system disorders | ||||
| Anemia | 1 | 0 | 0 | 1 |
| Thrombocytopenia | 4 | 3 | 1 | 8 |
| Neutropenia | 0 | 0 | 1 | 1 |
| Cardiac disorders | ||||
| Atrial fibrillation | 1 | 0 | 0 | 1 |
| Supraventricular tachycardia | 0 | 1 | 0 | 1 |
| Palpitations | 1 | 0 | 0 | 1 |
| Constitutional | ||||
| Chills | 1 | 0 | 0 | 1 |
| Fatigue | 4 | 0 | 0 | 4 |
| Gastrointestinal disorders | ||||
| Diarrhea | 3 | 0 | 0 | 3 |
| Gastric ulcer/gastritis | 1 | 0 | 0 | 1 |
| Gastroesophageal reflux disease | 1 | 0 | 0 | 1 |
| Mucositis oral | 1 | 0 | 0 | 1 |
| Other | 1 | 0 | 0 | 1 |
| General disorders | ||||
| Edema limbs | 1 | 0 | 0 | 1 |
| Infections and infestations | ||||
| Ear infection/otitis media | 2 | 0 | 0 | 2 |
| Eye infection | 1 | 0 | 0 | 1 |
| Lung infection | 2 | 0 | 0 | 2 |
| Dental infection | 1 | 0 | 0 | 1 |
| Sinusitis | 2 | 0 | 0 | 2 |
| Skin infection | 4 | 0 | 0 | 4 |
| Upper respiratory infection | 2 | 0 | 0 | 2 |
| Urinary tract infection | 1 | 0 | 0 | 1 |
| Oral candidiasis | 1 | 0 | 0 | 1 |
| Metabolism and nutrition disorders | ||||
| Hyperglycemia | 1 | 2 | 0 | 3 |
| Hypokalemia | 0 | 1 | 0 | 1 |
| Musculoskeletal and connective tissue disorders | ||||
| Arthralgia | 3 | 0 | 0 | 3 |
| Myalgia | 2 | 0 | 0 | 2 |
| Lightheadedness | 1 | 0 | 0 | 1 |
| Headache | 0 | 1 | 0 | 1 |
| Presyncope | 1 | 0 | 0 | 1 |
| Respiratory, thoracic, and mediastinal disorders | ||||
| Cough | 3 | 0 | 0 | 3 |
| Dyspnea | 2 | 1 | 0 | 3 |
| Hypoxia | 1 | 0 | 0 | 1 |
| Epistaxis | 1 | 0 | 0 | 1 |
| Other | 2 | 0 | 0 | 2 |
| Skin and subcutaneous tissue disorders | ||||
| Skin and subcutaneous tissue disorders, rash | 5 | 1 | 0 | 6 |
| Skin and subcutaneous tissue disorders, other | 1 | 0 | 0 | 1 |
Grade ≥2 adverse events deemed by investigators to be possibly, probably, or definitely associated with protocol therapy are shown. Number of individual patients with the indicated toxicity is shown, with the highest toxicity grade shown for an individual patient. In addition, 4 patients had grade 1 thrombocytopenia.